First-trimester maternal serum PP13 in the risk assessment for preeclampsia

Roberto Romero; Juan Pedro Kusanovic; Nandor Gabor Than; Offer Erez; Francesca Gotsch; Jimmy Espinoza; Samuel Edwin; Ilana Chefetz; Ricardo Gomez; Jyh Kae Nien; Marei Sammar; Beth Pineles; Sonia S. Hassan; Hamutal Meiri; Yossi Tal; Ido Kuhnreich; Zoltan Papp; Howard S. Cuckle

doi:10.1016/j.ajog.2008.01.013

First-trimester maternal serum PP13 in the risk assessment for preeclampsia

Roberto Romero, Juan Pedro Kusanovic, Nandor Gabor Than, Offer Erez, Francesca Gotsch, Jimmy Espinoza, Samuel Edwin, Ilana Chefetz, Ricardo Gomez, Jyh Kae Nien, Marei Sammar, Beth Pineles, Sonia S. Hassan, Hamutal Meiri, Yossi Tal, Ido Kuhnreich, Zoltan Papp, Howard S. Cuckle

Research output: Contribution to journal › Article › peer-review

134 Scopus citations

Abstract

Objective: The objective of the study was to determine whether first-trimester maternal serum placental protein 13 (PP13) concentrations can be used in the risk assessment for preeclampsia. Study Design: This case-control study included 50 patients with preeclampsia and 250 patients with normal pregnancies. Samples were collected between 8 and 13 weeks of gestation. Serum PP13 concentrations were measured by immunoassay and expressed as medians and multiples of the median (MoM) for gestational age. Sensitivity and specificity were derived from receiver-operating characteristic curve analysis. Results: (1) Serum PP13 concentration in the first trimester was significantly lower in patients who developed preterm and early-onset preeclampsia than in those with normal pregnancies; and (2) at 80% specificity, a cutoff of 0.39 MoM had a sensitivity of 100% for early-onset preeclampsia and 85% for preterm preeclampsia. Conclusion: Maternal serum first-trimester PP13 appears to be a reasonable marker for risk assessment for preterm preeclampsia but a weak marker for severe preeclampsia at term, and ineffective for identifying mild preeclampsia at term.

Original language	English
Pages (from-to)	122.e1-122.e11
Journal	American Journal of Obstetrics and Gynecology
Volume	199
Issue number	2
DOIs	https://doi.org/10.1016/j.ajog.2008.01.013
State	Published - 1 Jan 2008
Externally published	Yes

Keywords

high-risk pregnancy
maternal serum biochemistry
prenatal care
risk assessment
screening

ASJC Scopus subject areas

Obstetrics and Gynecology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ajog.2008.01.013

Cite this

Romero, R., Kusanovic, J. P., Than, N. G., Erez, O., Gotsch, F., Espinoza, J., Edwin, S., Chefetz, I., Gomez, R., Nien, J. K., Sammar, M., Pineles, B., Hassan, S. S., Meiri, H., Tal, Y., Kuhnreich, I., Papp, Z., & Cuckle, H. S. (2008). First-trimester maternal serum PP13 in the risk assessment for preeclampsia. American Journal of Obstetrics and Gynecology, 199(2), 122.e1-122.e11. https://doi.org/10.1016/j.ajog.2008.01.013

@article{5ad4e2ccc9f249eab00113548e1c6db6,

title = "First-trimester maternal serum PP13 in the risk assessment for preeclampsia",

abstract = "Objective: The objective of the study was to determine whether first-trimester maternal serum placental protein 13 (PP13) concentrations can be used in the risk assessment for preeclampsia. Study Design: This case-control study included 50 patients with preeclampsia and 250 patients with normal pregnancies. Samples were collected between 8 and 13 weeks of gestation. Serum PP13 concentrations were measured by immunoassay and expressed as medians and multiples of the median (MoM) for gestational age. Sensitivity and specificity were derived from receiver-operating characteristic curve analysis. Results: (1) Serum PP13 concentration in the first trimester was significantly lower in patients who developed preterm and early-onset preeclampsia than in those with normal pregnancies; and (2) at 80% specificity, a cutoff of 0.39 MoM had a sensitivity of 100% for early-onset preeclampsia and 85% for preterm preeclampsia. Conclusion: Maternal serum first-trimester PP13 appears to be a reasonable marker for risk assessment for preterm preeclampsia but a weak marker for severe preeclampsia at term, and ineffective for identifying mild preeclampsia at term.",

keywords = "high-risk pregnancy, maternal serum biochemistry, prenatal care, risk assessment, screening",

author = "Roberto Romero and Kusanovic, {Juan Pedro} and Than, {Nandor Gabor} and Offer Erez and Francesca Gotsch and Jimmy Espinoza and Samuel Edwin and Ilana Chefetz and Ricardo Gomez and Nien, {Jyh Kae} and Marei Sammar and Beth Pineles and Hassan, {Sonia S.} and Hamutal Meiri and Yossi Tal and Ido Kuhnreich and Zoltan Papp and Cuckle, {Howard S.}",

note = "Funding Information: This research was supported, in part, by the Intramural Research Program of the National Institute of Child Health and Human Development, Eunice Kennedy Shriver National Institutes of Health, Department of Health and Human Services, and Grants 31851 and 42872 from Israel Chief Scientist (to H.M.). ",

year = "2008",

month = jan,

day = "1",

doi = "10.1016/j.ajog.2008.01.013",

language = "English",

volume = "199",

pages = "122.e1--122.e11",

journal = "American Journal of Obstetrics and Gynecology",

issn = "0002-9378",

publisher = "Mosby Inc.",

number = "2",

}

Romero, R, Kusanovic, JP, Than, NG, Erez, O, Gotsch, F, Espinoza, J, Edwin, S, Chefetz, I, Gomez, R, Nien, JK, Sammar, M, Pineles, B, Hassan, SS, Meiri, H, Tal, Y, Kuhnreich, I, Papp, Z & Cuckle, HS 2008, 'First-trimester maternal serum PP13 in the risk assessment for preeclampsia', American Journal of Obstetrics and Gynecology, vol. 199, no. 2, pp. 122.e1-122.e11. https://doi.org/10.1016/j.ajog.2008.01.013

TY - JOUR

T1 - First-trimester maternal serum PP13 in the risk assessment for preeclampsia

AU - Romero, Roberto

AU - Kusanovic, Juan Pedro

AU - Than, Nandor Gabor

AU - Erez, Offer

AU - Gotsch, Francesca

AU - Espinoza, Jimmy

AU - Edwin, Samuel

AU - Chefetz, Ilana

AU - Gomez, Ricardo

AU - Nien, Jyh Kae

AU - Sammar, Marei

AU - Pineles, Beth

AU - Hassan, Sonia S.

AU - Meiri, Hamutal

AU - Tal, Yossi

AU - Kuhnreich, Ido

AU - Papp, Zoltan

AU - Cuckle, Howard S.

N1 - Funding Information: This research was supported, in part, by the Intramural Research Program of the National Institute of Child Health and Human Development, Eunice Kennedy Shriver National Institutes of Health, Department of Health and Human Services, and Grants 31851 and 42872 from Israel Chief Scientist (to H.M.).

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Objective: The objective of the study was to determine whether first-trimester maternal serum placental protein 13 (PP13) concentrations can be used in the risk assessment for preeclampsia. Study Design: This case-control study included 50 patients with preeclampsia and 250 patients with normal pregnancies. Samples were collected between 8 and 13 weeks of gestation. Serum PP13 concentrations were measured by immunoassay and expressed as medians and multiples of the median (MoM) for gestational age. Sensitivity and specificity were derived from receiver-operating characteristic curve analysis. Results: (1) Serum PP13 concentration in the first trimester was significantly lower in patients who developed preterm and early-onset preeclampsia than in those with normal pregnancies; and (2) at 80% specificity, a cutoff of 0.39 MoM had a sensitivity of 100% for early-onset preeclampsia and 85% for preterm preeclampsia. Conclusion: Maternal serum first-trimester PP13 appears to be a reasonable marker for risk assessment for preterm preeclampsia but a weak marker for severe preeclampsia at term, and ineffective for identifying mild preeclampsia at term.

AB - Objective: The objective of the study was to determine whether first-trimester maternal serum placental protein 13 (PP13) concentrations can be used in the risk assessment for preeclampsia. Study Design: This case-control study included 50 patients with preeclampsia and 250 patients with normal pregnancies. Samples were collected between 8 and 13 weeks of gestation. Serum PP13 concentrations were measured by immunoassay and expressed as medians and multiples of the median (MoM) for gestational age. Sensitivity and specificity were derived from receiver-operating characteristic curve analysis. Results: (1) Serum PP13 concentration in the first trimester was significantly lower in patients who developed preterm and early-onset preeclampsia than in those with normal pregnancies; and (2) at 80% specificity, a cutoff of 0.39 MoM had a sensitivity of 100% for early-onset preeclampsia and 85% for preterm preeclampsia. Conclusion: Maternal serum first-trimester PP13 appears to be a reasonable marker for risk assessment for preterm preeclampsia but a weak marker for severe preeclampsia at term, and ineffective for identifying mild preeclampsia at term.

KW - high-risk pregnancy

KW - maternal serum biochemistry

KW - prenatal care

KW - risk assessment

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=48149087254&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2008.01.013

DO - 10.1016/j.ajog.2008.01.013

M3 - Article

AN - SCOPUS:48149087254

SN - 0002-9378

VL - 199

SP - 122.e1-122.e11

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

IS - 2

ER -

First-trimester maternal serum PP13 in the risk assessment for preeclampsia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this